Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System
Chembio announced the submission to the FDA for a Clinical Laboratory Improvement Amendments waiver for the DPP HIV-Syphilis System.
Read MorePosted by Andy Lundin | Nov 28, 2022 | Sexually Transmitted Diseases |
Chembio announced the submission to the FDA for a Clinical Laboratory Improvement Amendments waiver for the DPP HIV-Syphilis System.
Read MorePosted by Andy Lundin | Nov 25, 2022 | Covid 19 |
The National Institutes of Health (NIH) Launched a new website where users can report a positive or negative test result.
Read MorePosted by Chris Wolski | Nov 23, 2022 | Molecular Diagnostic Analyzers, POC Rapid Assays, Sexually Transmitted Diseases |
Bacterial vaginosis and trichomoniasis results in a range of health complications. A test-and-treat approach can improve diagnosis.
Read MorePosted by Chris Wolski | Nov 14, 2022 | Diagnostic Technologies |
Clinical laboratory experts predict continued importance on COVID testing, ongoing technician shortages, and more in 2023.
Read MorePosted by Chris Wolski | Nov 9, 2022 | Molecular Diagnostic Analyzers |
UK diagnostics manufacturer, Llusern Scientific, will preview its Lodestar DX molecular diagnostic platform at the upcoming Medica 2022.
Read More